Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Saxagliptin on Gut Microbiota in Newly Diagnosed Type 2 Diabetes
NCT02583438Phase 4Unknown
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of saxagliptin in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Beijing Chaoyang Hospital. Primary endpoint: Change from Baseline Bacteroidetes abundances and composition of gut microbiota at 6 months. Status: unknown.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02583438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583438.